Newron Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9%.

Top 20 shareholders own 11.12% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
4.93%	Tobias Scherer	960,000	US$7.9m	12.3%	no data
3.08%	UBS Asset Management AG	599,762	US$4.9m	170%	no data
0.63%	ZKB Asset Management	123,154	US$1.0m	1.58%	no data
0.47%	Zürcher Kantonalbank, Investment Arm	91,493	US$749.5k	-8.37%	0.01%
0.39%	Heights Capital Management, Inc.	75,008	US$614.5k	-90%	0.25%
0.28%	Pictet Asset Management SA	53,804	US$440.8k	0%	no data
0.24%	BlackRock, Inc.	47,556	US$389.6k	0.64%	no data
0.22%	Ravi Anand	41,872	US$343.0k	0%	no data
0.21%	Ulrich Köstlin	40,249	US$329.7k	0%	no data
0.13%	Wyss & Partner AG	25,000	US$204.8k	0%	0.41%
0.11%	BCV Asset Management	21,000	US$172.0k	90.9%	no data
0.1%	Stefan Weber	20,351	US$166.7k	0%	no data
0.062%	Patrick Langlois	12,000	US$98.3k	0%	no data
0.062%	Kb - Vermögensverwaltung GmbH	12,000	US$98.3k	0%	0.17%
0.059%	Knoesel & Ronge Vermögensverwaltung GmbH & Co. Kg	11,500	US$94.2k	0%	0.14%
0.056%	Lombard Odier Asset Management (Switzerland) SA	10,990	US$90.0k	131%	no data
0.048%	amandea Vermögensverwaltung AG	9,262	US$75.9k	0%	0.18%
0.019%	Migrosbank Asset Management	3,619	US$29.6k	0%	no data
0.013%	Roberto Galli	2,500	US$20.5k	0%	no data
0.013%	State Street Global Advisors, Inc.	2,463	US$20.2k	0%	no data